Enhanced predictive validity of integrative models for refractory hyperthyroidism considering baseline and early therapy characteristics: a prospective cohort study

Table 5 Refractory odds ratios for characteristics of baseline and early therapy in medium–low cumulative dosage subgroup

Characteristics of baseline and early therapy (Medium–low)^a	Combined multivariate analyses
	Refractory, % (n/N)	OR (95% CI)	P value
Age, year
≥ 36	35.0 (43/123)	Reference
< 36	55.0 (60/109)	1.8 (1.0–3.4)	0.054
GO, n (%)
Yes	57.4 (31/54)	2.0 (1.0–4.2)	0.060
No	40.4 (72/178)	Reference
Initial goiter size (cm³)
≥ 11.5	52.5 (93/177)	5.2 (2.2–12.6)	< 0.001
< 11.5	18.2 (10/55)	Reference
Initial fT3 (pmol/L)
≥ 31.3	63.3 (31/49)	1.8 (0.6–5.3)	0.289
< 31.3	39.3 (72/183)	Reference
Initial fT4 (pmol/L)
≥ 67.7	58.8 (40/68)	1.8 (0.7–5.1)	0.244
< 67.7	38.4 (63/164)	Reference
Initial TRAb (IU/L)
≥ 17.5	68.8 (44/64)	3.0 (1.1–8.5)	0.036
< 17.5	35.1 (59/168)	Reference
fT4 (3 m)^b (pmol/L)
≥ 21.0	57.5 (50/87)	1.2 (0.6–2.4)	0.536
< 21.0	36.6 (53/145)	Reference
fT4 (3 m percentage decrease)^c (%)
≥ 54.6	39.5 (62/157)	Reference
< 54.6	54.7 (41/75)	3.7 (1.7–7.9)	0.001
TRAb (3 m accumulation)^d (day* IU/L)
≥ 1051.5	62.0 (49/79)	1.2 (0.4–3.0)	0.775
< 1051.5	35.3 (54/153)	Reference

GO Graves’ orbitopathy, fT3 free triiodothyronine, fT4 free thyroxine, TRAb thyroid stimulating hormone receptor autoantibody, OR odds ratio, CI confidence interval; m, month
^a3-month medium–low cumulative MMI dosage group (< 1730 mg, average < 20 mg/day, N = 232)
^bAbsolute serum fT4 level at 3 months of MMI therapy
^cDecrease percentage of serum fT4 level at 3 months of MMI therapy compared with the serum levels before therapy
^dThe area under the fitted curve of 0–3 months serum TRAb level after the start of MMI therapy (the abscissa is the days, the ordinate is the TRAb level)

ISSN: 1479-5876